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Introduction
Guidelines for management of type 2 diabetes mellitus (T2DM) recommend metformin as the first-line treatment unless contraindicated, followed by a stepwise intensification with other oral antidiabetes drugs (OADs) aimed at maintaining glycated haemoglobin (HbA1c) levels <7.0% [1, 2] . In patients who are intolerant (gastrointestinal [GI] disturbances) or contraindicated (renal impairment, congestive heart failure) to metformin, sulphonylureas (SUs) are often still the preferred first-line treatment option [3] . Additionally, in countries such as India, SUs are frequently prescribed as first-line treatment due to their efficacy and low economic burden, particularly in lean patients [4] . Although SUs have good initial efficacy in recently diagnosed patients, they are often associated with higher rate of secondary failure [5] , which eventually leads to addition of other OADs to maintain glycaemic control. Several OADs other than metformin, such as ␣-glucosidase inhibitors (␣-GI), glinides, thiazolidinediones (TZDs), dipeptidyl peptidase (DPP)-4 inhibitors, or sodium-glucose cotransporter (SGLT)-2 inhibitors, are now available for use as add-on. However, an add-on should be selected considering patient's characteristics (clinical profile, co-morbidities, and personal preferences) and safety profile (hypoglycaemia and weight gain) of various OADs. New therapeutic drug classes such as DPP-4 inhibitors could offer solutions for some of the challenges physicians face in clinical practice while intensifying treatment. The combination therapy of a SU (increases insulin secretion) and a DPP-4 inhibitor (increases insulin secretion and modulates glucagon secretion in a glucose-dependent manner) targets multiple pathophysiological defects of T2DM [6] [7] [8] . In addition, DPP-4 inhibitors by themselves do not increase the risk of hypoglycaemia [7, 9] .
The Effectiveness of Diabetes control with vildaGliptin and vildagliptin/mEtformin (EDGE) study was a large, 1-year, reallife, observational study, which assessed the effectiveness and safety of adding a DPP-4 inhibitor (vildagliptin) vs. other OADs (metformin; any SU, TZD, ␣-GI or glinide) in 45,868 patients with T2DM inadequately controlled on monotherapy [10] . Physician could prescribe any add-on agent to failing monotherapy and accordingly patients were assigned to vildagliptin cohort or other OAD cohort. As expected, majority (approximately 82%) of the patients enrolled in the EDGE study were on first-line therapy with metformin. The overall results (vildagliptin + first-line therapy vs. other OADs + first-line therapy) and results of the sub analysis (vildagliptin + metformin vs. SU + metformin) are already published [10, 11] . However, to date, limited evidence is available to guide physicians' choice of a second-line OAD after SU monotherapy failure in patients who cannot receive metformin. Therefore, it is of clinical importance to investigate the effectiveness and safety of various OADs as add-on to SU monotherapy.
The pragmatic design of the EDGE study and the large enrolled population at the time when DPP-4 inhibitors were launched as a new therapeutic alternative offered an unique opportunity to explore the real-world effectiveness and safety of a DPP-4 inhibitor vs. comparator OADs (any ␣-GI, TZD, glinide) in patients failing on SU monotherapy and who did not receive metformin. The current exploratory post hoc analysis included the overall EDGE population and patients enrolled from India.
Methods

Study design and patients
EDGE was a 1-year, prospective, observational study conducted in 27 countries. The study design and patient inclusion/exclusion criteria are extensively described elsewhere [10] . In brief, patients aged >18 years who were inadequately controlled on OAD monotherapy and were prescribed an additional OAD by their physician were included in the study. The choice of add-on therapy was at the physician's discretion. To avoid bias in the selection of second OAD, enrolment was confirmed after the patients were prescribed the add-on therapy. All the patients provided consent for data collection. Patients were assigned to one of two groups: DPP-4 inhibitor (vildagliptin) or comparator (metformin; any SU, TZD, glinide or ␣-GI). This exploratory analysis included patients (overall and India) inadequately controlled on SU monotherapy and who were prescribed an add-on OAD other than metformin. Data were collected at baseline and at any point during the 1-year observation period, with a compulsory visit at month 12.
Study assessments
The primary effectiveness endpoint of this post hoc analysis, as in the original protocol, was the proportion of patients achieving a clinically relevant reduction in HbA1c, defined as a drop of >0.3%, without any tolerability findings (hypoglycaemia, discontinuation due to GI side effects, peripheral oedema or weight gain [≥5%]). The secondary effectiveness endpoint was the composite of glycaemic response, defined as achieving HbA1c <7.0%, without hypoglycaemia or weight gain ≥3%. Changes in HbA1c and body weight from baseline to the end of the 12-month observation period were also assessed. Safety assessments included recording incidence and severity of all adverse events (AEs) as well as their relationship to the treatment.
Statistical analysis
All analyses were conducted for the intention-to-treat population, which included patients who received at least one dose of the new add-on agent. Baseline and safety data were descriptively summarised for both groups. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable logistic regression models for the primary and secondary effectiveness endpoints. The OR expresses odds in favour of success (patients achieving endpoints) with vildagliptin relative to comparators. As this analysis was not prespecified in the protocol, only unadjusted ORs are presented. Changes in HbA1c and body weight were analysed using analysis of covariance (ANCOVA) model and were adjusted for covariates (treatment arm and the respective baseline clinical characteristics). Approximately 40% of patients included in this post hoc
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Patients on background SU monotherapy* (N=3756)
Patients from India (N=302) TZDs (n=214) α-GIs (n=66) Glinides (n=22) *Patients enrolled in the EDGE study on prior treatment with SU monotherapy α-GIs, alpha glucosidase inhibitors; SUs, sulphonylureas; TZDs, thiazolidinediones analysis were enrolled from India and >65% in the comparator arm were on TZDs, and thus, as part of sensitivity analyses, all the statistical analyses were also performed in both Indian and TZD subsets. All statistical analyses were performed using SAS software, version 9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Results
Patient disposition and baseline demographics
Of the 45,868 patients enrolled worldwide, 3756 (n = 1554; Indian subset) were receiving SU monotherapy. Upon treatment intensification, 2936 patients received vildagliptin (n = 1252; Indian subset) and 820 (n = 302; Indian subset) received comparators as add-on. The most widely prescribed add-on to SU monotherapy in the comparator group was TZD (n = 536) ( Fig. 1 
Overall results
The ORs for achieving the primary and secondary effectiveness endpoints are presented in . After 1 year of treatment, the adjusted mean reduction in HbA1c was −1.4% for the vildagliptin group and −1.2% for the comparator group, with a mean between-group difference of −0.2% (p < 0.0001). The adjusted mean body weight reduction was higher in the vildagliptin group (−1.1 kg) than in the comparator group (−0.3 kg), with a between-treatment difference of −0.8 kg (p < 0.0001) (Fig. 2) . The between-treatment difference in weight change vs. TZDs was −1.4 kg (p < 0.0001). The incidence of total AEs was low in general; the incidence was lower in the vildagliptin group compared with the comparator group (vildagliptin: 7.0%, n = 204; comparator: 8.2%, n = 67). The incidence of AEs in patients who were prescribed TZDs was 5.2% (n = 43). AEs that occurred during the study in >0.5% of patients, listed by primary system organ class (SOC), are summarised in Table 3 . The most commonly reported AEs by primary SOC in both groups were GI disorders, infections and infestations. The overall incidence of hypogly- Table 1 -Demographics and baseline characteristics of the overall population and the Indian subset.
Overall
Indian subset
SU+comparator a n = 820
Total n = 3756
SU+comparator a n = 302 Values are presented as mean ± SD or n (%). Weight data were missing for 133 and 67 patients; BMI data were missing for 134 and 67 patients; HbA1c data were missing for 203 and 99 patients in the overall and Indian subset, respectively. a Comparator includes any TZD, ␣-GI or glinide.
␣-GI, alpha glucosidase inhibitor; BMI, body mass index; OAD, oral antidiabetes drug; SU, sulphonylurea; TZD, thiazolidinedione; T2DM, type 2 diabetes mellitus. caemic events was low: 0.9% (n = 27) in the vildagliptin group and 1.2% (n = 10) in the comparator group. The incidence of severe hypoglycaemia was 0.2% (n = 6) and 0.4% (n = 3) in the vildagliptin and comparator groups, respectively. The incidences of hypoglycaemia and severe hypoglycaemia were 1.5% (n = 8) and 0.6% (n = 3), respectively in patients who received TZDs.
Indian subset
Similar to the results in the overall population, vildagliptin showed a better treatment response for both primary and secondary effectiveness endpoints in patients enrolled in India. Overall, 64.9% of patients in the vildagliptin group and 57.3% in the comparator group achieved an HbA1c reduction of >0.3% without any predefined tolerability issues, resulting in an OR of 1.4 (95% CI: 1.07, 1.78; p = 0.0134) in favour of vildagliptin. The OR was 1.6 (95% CI: 1.17, 2.10; p = 0.0027) in favour of vildagliptin compared with that in patients who were prescribed TZDs. The composite endpoint of HbA1c <7.0% without hypoglycaemia or weight gain was achieved by 20.5% and 11.6% of patients in the vildagliptin and comparator groups, respectively. The OR was 2.0 (95% CI: 1.32, 2.94; p < 0.0009) in favour of vildagliptin, the corresponding OR was 2.3 (95% CI: 1.40, 3.76; p < 0.0010) vs. the patients who were on TZDs. The adjusted mean reduction in HbA1c was higher for the vildagliptin group (−1.4%) compared with that for the comparator group (−1.2%) with a statistically significant between-treatment difference (−0.3%; p < 0.0001). The change in body weight after 1 year of treatment was −0.7 kg in the vildagliptin group and +0.5 kg in the comparator group (between-treatment difference, −1.2 kg; p < 0.0001) (Fig. 2) . The between-treatment difference in weight change vs. TZDs was −1.4 kg (p < 0.0001). The incidence of total AEs was 5.5% (n = 69) and 10.3% (n = 31) in the vildagliptin and comparator groups, respectively. The incidence of total AEs in patients who were prescribed TZDs was 6.0% (n = 18). The incidence of hypoglycaemia was two-fold higher in the comparator group (2.3%, n = 7) compared with vildagliptin group (1.1%, n = 14); incidence of severe hypoglycaemia was 0.4% (n = 5) in the vildagliptin group and 1.0% (n = 3) in the comparator group. The incidences of hypoglycaemia and severe hypoglycaemia were 2.3% (n = 5) and 1.4% (n = 3), respectively, in patients who received TZDs.
Discussion
For patients on SU monotherapy, in whom metformin is contraindicated, there are no (or only limited) specific recommendations for the optimal second-line agent. Early treatment intensification in patients with first-line SU is warranted to prevent further deterioration of glycaemic control, as SUs are associated with higher rate of secondary failure, and several patients are diagnosed at a younger age (in countries such as India). This exploratory post hoc analysis of the EDGE study provides new insights into the treatment of patients with T2DM inadequately controlled on SU monotherapy. The results of this post hoc analysis showed that the mean HbA1c at the time of adding the second OAD was high in both the overall population (8.5%) and the Indian subset (8.7%), reflecting insufficient glycaemic control. There seems to be a delay in treatment intensification with second OAD, despite the longer T2DM duration (∼6 years) and high baseline HbA1c, suggesting the presence of clinical inertia. In addition, intensification of the failing SU therapy was delayed even further compared with the overall EDGE data. Prospective work targeted at educating physicians and patients regarding early treatment intensification might help improve overall outcomes [12] .
Apart from vildagliptin, the most widely prescribed OAD as an add-on to SU monotherapy was TZD, particularly in India. This is logical, as TZDs act by improving insulin resistance [13] , complementing the effect of SUs. However, this combination is associated with adverse effects like weight gain and fluid retention [14] . Additionally, caution is suggested when prescribing TZDs to patients with congestive heart failure [15] .
After 1 year of treatment, a significantly higher proportion (∼50%) of patients achieved a clinically meaningful HbA1c reduction of >0.3% without any tolerability issues with addition of vildagliptin. This highlights the importance of timely identification of treatment failure and appropriate intensification with well-tolerated agents such as DPP-4 inhibitors. In accordance with the treatment guidelines, which recommend maintaining HbA1c <7.0% without hypoglycaemia and weight gain, the odds for achieving HbA1c <7.0% without hypoglycaemia and weight gain were almost twice in patients receiving vildagliptin vs. comparators. Moreover, the mean HbA1c reductions were significantly higher with vildagliptin relative to comparators. In addition to significant HbA1c reductions and decreased risk of hypoglycaemic events, treatment with vildagliptin also resulted in significant weight loss relative to comparators; this difference was more pronounced in comparison with TZDs. In general, vildagliptin in comparison with comparators was well tolerated, with an overall low incidence of AEs (7.0% vs. 8.2%) and hypoglycaemia (0.9% vs.
1.2%).
Patients enrolled from India were younger, had lower BMI and higher baseline HbA1c when compared with the overall population. A higher proportion of patients from India in the vildagliptin and comparator groups achieved HbA1c reduction >0.3% without any tolerability issues when compared with the overall group. On the contrary, a lower proportion of patients from India reached HbA1c <7.0% without any tolerability issues. The differences in the results may be possibly driven by high HbA1c in the Indian subset. The incidence of AEs was low in general and similar across the Indian and overall population.
Several studies have evaluated the efficacy and safety of DPP-4 inhibitors as add-on to SU under randomised and reallife settings [16] [17] [18] . However, most of the patients enrolled were either receiving or received treatment with metformin in addition to SU and DPP-4 inhibitor and, none of the studies has reported outcomes for patients with first-line SU monotherapy for whom metformin is not an option.
Interpretation of the results of this post hoc analysis should consider its limitations. The EDGE study was conducted at a time when DPP-4 inhibitors were being launched and was designed to assess the effectiveness and safety of vildagliptin compared with other OADs (except SGLT-2 inhibitors which were not yet approved) under real-life settings. The information regarding duration or therapeutic doses of the SU therapy were lacking, but based on the baseline HbA1c levels reported, patients might have been on SUs for a long time and some may have even developed resistance to SU-induced hypoglycaemia. As this was a secondary analysis and not pre-specified in the protocol, the results were not adjusted for potential baseline and demographic confounders. The young age at diagnosis, low BMI and high baseline HbA1c of the patients enrolled from India are characteristics of Latent Autoimmune Diabetes in Adults (LADA), however, glutamic acid decarboxylase (GAD) autoantibodies were not measured in this real-life study to confirm the presence of LADA. Owing to the real-life nature of the study, some missing HbA1c and weight data and underreporting of AEs (patients were encouraged to report AEs voluntarily) might have affected the overall findings.
In general, this report and any such future reports on optimisation and intensification of the failing first-line SU monotherapy may contribute towards an evidencebased clinical practice, eventually benefiting patients on SU monotherapy with limited options for intensification.
Conclusions
In people with T2DM failing on SU monotherapy, vildagliptin as an add-on therapy resulted in a higher proportion of patients achieving clinically relevant HbA1c reductions without tolerability issues compared with other OADs. These data support the use of DPP-4 inhibitors such as vildagliptin in patients who require intensification of existing SU therapy and in whom metformin is contraindicated or not tolerated. 
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